-
Abstract Number: PB0556
Randomized Clinical Trial of PK-guided Treatment of Desmopressin Combined with FVIII Concentrate versus Only FVIII Concentrate in Peri-operative Hemophilia A Patients: Final Results of the Little DAVID Study
-
Abstract Number: PB0969
Rapid and Complete Clearance of HPA-1a Mismatched Platelets in a Human Model of Fetal and Neonatal Alloimmune Thrombocytopenia by a Hyperimmune Plasma Derived Polyclonal Anti HPA-1a Antibody
-
Abstract Number: PB0049
Rapid Detection of DOACs in DVT Patients Using a Single-use Microfluidic Chip under Whole Blood Flow
-
Abstract Number: PB1035
Rapid Internalization and Nuclear Translocation of CCL5 and CXCL4 in Endothelial Cells
-
Abstract Number: PB0708
Rare Bleeding Disorders in Children. Towards Establishing a Local Registry
-
Abstract Number: PO187
Rare Complications of DOAC Treatment
-
Abstract Number: PB0037
Rat Model of Metabolic Disorders: Dynamics of Hemostasis and Endothelial Function Changes
-
Abstract Number: PB0609
Rationale and Design of the “International Registry on the Symptomatic Hemophilia A/B Carriers”
-
Abstract Number: PB0564
Real World Data on Haemophilia A Patients Switching to rFVIIIFc Treatment in Greece. Interim Results from the Multicenter Observational Study TOOL
-
Abstract Number: PO164
Real World Experience Use of DOAC in APLS Patients
-
Abstract Number: PB0637
Real World Experience with Emicizumab with Hemophilia A Treated in Private Practice in Mexico
-
Abstract Number: PB0577
Real-world Annual Bleeding Rate in People with Severe Hemophilia A without Inhibitor on Prophylaxis, Comparing Switched to rFVIII-Fc versus Non-switched Patients: A Multicentre, Retrospective, Non interventional, before-after Study with the French BERHLINGO Database (MOTHIF-II)
-
Abstract Number: PB0452
Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in France: Findings from the CHESS II Study
-
Abstract Number: PB0487
Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in Germany: Findings from the CHESS II Study
-
Abstract Number: PB0464
Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in Italy: Findings from the CHESS II Study
-
Abstract Number: PB0456
Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in Spain: Findings from the CHESS II Study
-
Abstract Number: PB0479
Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in the United Kingdom: Findings from the CHESS II Study
-
Abstract Number: PB1252
Real-world Data on the Use of Oral Anticoagulants for the Treatment of Venous Thromboembolism in Sweden: Oral Anticoagulant Use and Baseline Characteristics from the Venous Thromboembolism Treatment Study
-
Abstract Number: PB0099
Real-world Effectiveness of BAY 94-9027 to Treat Hemophilia A in the ATHNdataset
-
Abstract Number: PB0537
Real-world Experience in Introducing Emicizumab Prophylaxis for Adults with Haemophilia A without Inhibitors
-
Abstract Number: PB0677
Real-world Experience of Emicizumab Treatment Using Entire Vials Only
-
Abstract Number: PB0645
Real-world Experience of rIX-FP Prophylaxis at Dosing Intervals of up to 14 Days in a Pediatric Patient with Hemophilia B during the COVID-19 Pandemic
-
Abstract Number: PB0550
Real-world Joint Bleeding Rates in Patients with Congenital Hemophilia and Inhibitors: Final Data from the FEIBA Global Outcome (FEIBA GO) Study
-
Abstract Number: PB0463
Real-world Outcomes in People with Severe Hemophilia B Receiving FIX Prophylaxis across Europe: A CHESS II Analysis
-
Abstract Number: PB0551
Real-world Usage of rFIXFc in Sweden: A Report from the Swedish National Registry for Bleedings Disorders
-
Abstract Number: OC 08.4
Real-world Use of Damoctocog Alfa Pegol in Patients with Hemophilia A: Analysis of PK Profiles and Treatment Regimen Data from the WAPPS-Hemo Database
-
Abstract Number: PB0501
Real-world Use of FVIII in People with Severe Hemophilia A without Inhibitor on Prophylaxis, Comparing Switched to rFVIII-Fc versus Non-switched Patients: A Multicentre, Retrospective, Non Interventional, before-after Study with the French Nationwide Claims Database (MOTHIF-II)
-
Abstract Number: PB0946
Reclassification of von Willebrand Disease Classification and Effects of Vascular Dysfunction on von Willebrand Factor
-
Abstract Number: LPB0006
Recombinant Heparin: An Old Drug for the Modern World
-
Abstract Number: PB0605
Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia
-
Abstract Number: OC 45.4
Recovery of BAY 94-9027 [Jivi®] with One-stage Clotting and Chromogenic Assays: A Multicentre Study
-
Abstract Number: PB1199
Recurrence and Mortality Following First Venous Thromboembolism among Saudi Population: Single-centre Cohort Study
-
Abstract Number: PB1242
Recurrent Thromboembolic Risk in Paroxysmal Nocturnal Hemoglobinuria Patients not on Anticoagulation Treated with Terminal Complement Inhibition
-
Abstract Number: PO124
Recurrent Thrombosis and Antithrombin Deficiency
-
Abstract Number: PB1273
Recurrent Thrombosis Rescued by Fondaparinux in High-risk Patients: Case Series and Review of Literature
-
Abstract Number: PB0582
Reducing the Time of HAL and pedHAL Assessment
-
Abstract Number: PB0115
Refining and Validating a Model of FXI Activation and Activity in Thrombin Generation and Blood Coagulation
-
Abstract Number: PB0444
Refractory Acquired Hemophilia A (Even More) Complicated with SARS-CoV-2 Infection
-
Abstract Number: PB0824
Refractory Immune Thrombocytopenia (ITP): The Combination of Thrombopoietin Analogs and Immunosuppressants, Experience in a Single Spanish Center
-
Abstract Number: PO161
Refractory Thrombotic Thrombocytopenic Purpura – A Case Report
-
Abstract Number: PB0711
Registry of Patients with Congenital Bleeding Disorders from a Single Centre: Clinical and Analytical Characteristics
-
Abstract Number: OC 16.2
Regulation of Endothelial Cell Procoagulant Activity by TMEM16 Scramblases
-
Abstract Number: OC 10.1
Regulation of P2Y12 Receptor Expression and Activity by cAMP Mediated PKA Signalling in Human Platelets; A Novel Mode of Action of Anti-platelet Drugs?
-
Abstract Number: PO134
Reinforcement of Platelets Activity in Patients with Acute Myeloid Leukemia (AML) and Concomitant COVID-19 Infection
-
Abstract Number: PB0298
Relationship between von Willebrand Factor and Clinical Outcome in Patients with Severe COVID-19
-
Abstract Number: OC 34.3
Remote History of Venous Thrombosis and the Risk of Venous Thrombosis beyond the Age of 70 Years
-
Abstract Number: LPB0104
Resistance to Fibrinolysis in Critically Ill Patients with COVID-19 Can Be Overcome by N-acetylcysteine in vitro
-
Abstract Number: PB0803
Resolution Rates of Provoked Deep Vein Thrombosis and Pulmonary Embolism in Pediatric Patients Managed at a Tertiary Care Center
-
Abstract Number: OC 13.2
Response to Treatment for Gastro-intestinal Bleeding in Patients Affected by von Willebrand Disease
-
Abstract Number: PB0662
Responses to Anxiety and Depression Items in People with Hemophilia who Tested a Patient Reported Outcome Measure: The coreHEM MH Study
-
Abstract Number: OC 18.1
Result of a Study on Inter-laboratory Variability in the Measurement of Emicizumab and the Interference of Emicizumab in a Variety of Coagulation Tests
-
Abstract Number: PB0536
Results from the Eptacog Beta in the Treatment of Bleeding Episodes of all Severities in Pediatric Hemophilia A or B Patients with Inhibitors
-
Abstract Number: PB0796
Results of a Multinational Survey of Diagnosis, Practices and Expertise in the Management of Venous Thromboembolism (VTE) in Pediatric Patients with Sickle Cell Disease (SCD)
-
Abstract Number: LPB0138
Results of a Prospective, Observational, Multi-center Cohort Study of Venous Thromboembolism Outcomes in Thrombocytopenic Cancer Patients (TROVE Study)
-
Abstract Number: PB0928
Results of a Survey Regarding the Diagnosis, Investigation and Management of Unclassified Bleeding Disorders amongst United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) Members
-
Abstract Number: PB1238
Results of DOAC Dipstick Test in Outpatients with Venous Thromboembolic Disease Are Comparable to Plasma Levels of Direct Oral Inhibitors – An Efficient Assessment Tool
-
Abstract Number: PB0472
Results of Thrombin Generation Assay in Patients Treated with Emicizumab
-
Abstract Number: PB1030
Resveratrol Prevents Platelet Activation by Inhibition of ROS Formation
-
Abstract Number: PB1000
Reticulated Platelets in Healthy Volunteers. Relationships with Platelet Size Indexes and Platelet Activity
-
Abstract Number: PB0041
Reversal of Antithrombotic Effects of FXIa Inhibitor Milvexian (BMS-986177/JNJ-70033093) by Non-specific Agents in a Rabbit AV-shunt Model of Thrombosis
-
Abstract Number: PB0040
Reversal of Oral Anticoagulants: A Survey of Contemporary Practice Trends (ReACT)
-
Abstract Number: PB1160
Reversible Factor Xa Inhibitors Specifically Inhibit, in Clot Growth, via the Intrinsic Tenase Complex: A Tool to Determine Specifically the In- and Extrinsic Contribution to Clot Growth
-
Abstract Number: PB1311
Review of Intrapartum Management of ITP in Pregnancy in John Radcliffe Hospital
-
Abstract Number: PB0515
Reviewing HJHS as a Tool to Assess Outcome Measures in Patients with Haemophilia A in Australia
-
Abstract Number: PB0335
Ring Trial for Quality Assurance of the Manual Tilt Tube Technique for Prothrombin Time and INR Determinations in WHO Calibration Laboratories
-
Abstract Number: OC 12.4
Risk Factors for Gastrointestinal Bleeding in Patients with Gastrointestinal Cancer Using Edoxaban: Results from the Hokusai VTE Cancer Study
-
Abstract Number: PB0104
Risk Factors for Non-variceal Hemorrhage in Patients with Chronic Liver Disease
-
Abstract Number: PB1130
Risk Factors for Reccurence of Catheter Related upper Extremity Deep Venous Thrombosis in Cancer Patients
-
Abstract Number: PB1052
Risk Factors for Recurrent Thrombosis and Cause of Death in Patients with Antiphospholipid Syndrome; A Swedish Cohort Study
-
Abstract Number: PB1102
Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents with Lymphomas
-
Abstract Number: PO120
Risk Factors for Venous Thromboembolism at the University College Hospital, Ibadan
-
Abstract Number: PB1129
Risk Factors of Catheter-related Thrombosis in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
-
Abstract Number: PB1204
Risk Factors of Venous Thromboembolism at Patients with Endoscopic Urological Interventions
-
Abstract Number: PB0330
Risk of Misdiagnosis for Patients Presenting the Closed Variants E1359K or V1360A in Exon 28 of VWF due to a Major Discordance on VWF Activity Results between the VWF:GpIbM and VWF:GpIbR Assays
-
Abstract Number: PB1113
Risk of Vascular Occlusive Events with PARPis in Cancer: A Systematic Review and Meta-analysis
-
Abstract Number: OC 23.2
Risk of Venous and Arterial Thromboembolic Events in Patients Receiving Targeted Anti-cancer Therapy – A Nationwide Cohort Study
-
Abstract Number: PB1095
Risk of Venous Thromboembolism and Major Bleeding in the Clinical Course of Osteosarcoma and Ewing Sarcoma Patients
-
Abstract Number: OC 76.1
Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis – RIDTS Study
-
Abstract Number: PB1062
Rivaroxaban versus Vitamin K Antagonist for the Secondary Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: A Systematic Review and Meta-analysis
-
Abstract Number: PB0219
Role of Endothelium Activation Biomarkers in Prediction COVID-19 Related Intra-hospital Mortality
-
Abstract Number: PB0305
Role of Hematological Parameters in Stratification of Covid-19 Disease Severity
-
Abstract Number: PB1150
Role of Individual Venous Symptoms and Signs at Baseline in Predicting Future Development of Post-thrombotic Syndrome: Sub-analysis of the ATTRACT Trial
-
Abstract Number: PB1159
Role of Inherited Thrombophilia in the Occurrence of Arterial Thrombosis after Venous Thromboembolism
-
Abstract Number: LPB0097
Role of Low-dose Aspirin on the Release of Circulating Microvesicles in Patients at Cardiovascular Risk with and without Type 2 Diabetes
-
Abstract Number: PB0986
Role of Platelet GARP in TGFβ Activation
-
Abstract Number: PB0982
Role of Platelet HIF-2 Alpha to Indorse Thrombogenicity through Synthesis of PAI-1 during Hypoxia
-
Abstract Number: PB0981
Role of Platelet’s Heme Oxygenase-1 in Obese Patients with and without Type 2 Diabetes Mellitus
-
Abstract Number: OC 02.4
Role of Shear Stress and tPA Concentration in the Fibrinolytic Potential of Thrombi
-
Abstract Number: PB0865
Role of Soluble C5b-9 (sC5b-9) in Dosing Adjustments of Anti-complement Therapy during Pregnancy in a Patient with History of Atypical Hemolytic Uremic Syndrome (aHUS)
-
Abstract Number: LPB0018
Role of the “Mobile Loop” (Residues 142-150) in the Intrinsic Instability of TAFIa
-
Abstract Number: OC 42.1
Role of the Coagulation Factor XIII Binding Site on Crosslinking of Fibrinogen αC (233 – 425)
-
Abstract Number: PB0022
Role of the Interaction between Thrombophilia and Other Risk Factors in the Occurring of Ischemic Stroke in Young Patients: Algerian Restrospective Study about 75 Cases
-
Abstract Number: LPB0023
Role of Tissue Factor in Delayed Bone Repair Induced by Diabetic State in Mice
-
Abstract Number: PB1107
Role of Tissue Factor in the Procoagulant Shift of Endothelial Cells upon Exposure to Cancer Cell-derived Microparticles
-
Abstract Number: PB0233
Rotational Thromboelastometry (ROTEM) Profiling of COVID–19 Patients
-
Abstract Number: PB0706
ROTEM in Combination with Bleeding History – Can it Serve as a Screening Test for Factor XIII Deficiency in Patients with Suspected Bleeding Disorder?
-
Abstract Number: LPB0040
rs2431697 of miR-146a Regulates NETosis Determining the Thickness of the Carotid Intima-media in Patients with Rheumatoid Arthritis
-
Abstract Number: PB0439
Rutin Succinate Acts as an Anticoagulant and Inhibits Snake Venom Metalloproteinases in an Acute Thrombo-hemorrhagic Disorder Model
ISTH 2021 Congress
July 17-21, 2021. Philadelphia, PA.